track multipl clinic catalyst
aslan remain track multipl upcom clinic readout
includ pivot readout varlitinib pan-her inhibitor line
biliari tract cancer btc potenti intrigu earlier clinic
readout mid-stag pipelin
emerg mid-stag pipelin candid potenti materi near-
term valu creation catalyst may fulli appreci investor
 first-in-class dhodh inhibitor aml potenti
induc differenti aml cell aslan enrol aml patient
bid highest studi dose far patient current
on-going data expect achiev
materi interest investor
 inhibitor atop dermat
complet phase sad may recent iv data show rapid within
hour sustain day action recent clinic valid
mechan atop dermat potenti improv upon
dupix profil progress could also meaning
varlitinib pivot result btc data pivot
treetopp trial line btc could support acceler us approv
varlitinib treetopp assess varlitinib/capecitabin vs capecitabin
patient co-primari endpoint orr
success either orr signific one-sid level
signific one-sid level vs estim orr
month set model us launch line btc
op comment estimate e/ad estim
due time payment owe array biopharma arri rate
 vs estimate spend lower sg larg
in-line aslan revenu goe
varlitinib potenti estim peak revenu
remov gastric cancer due previou failur
asln valuat npv estim asln total
larg driven varlitinib global consider btc
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
engag
pharmaceut singapore-bas cayman island incorpor
biopharmaceut compani
develop
commerci
innov oncolog therapeut aslan
signific asset varlitinib promis oral revers novel pan-her
inhibitor target human epiderm growth factor receptor
caus excess prolif activ uncontrol cellular growth
varlitinib current multipl clinic trial multipl tumor
increas activ broad-bas signal inhibit aslan
seek demonstr varlitinib activ set
exhibit aslan drug develop pipelin varlitinib
mani tumor includ biliari tract gastric stomach cancer
other wide preval asian countri aslan materi
oper experi aslan therefor look region
varlitinib rapid effici clinic trial enrol develop still
retain potenti approv major market world-wide
trial includ potenti singl pivot studi
condit differ geograph region sever import
near-term data readout believ varlitinib activ differenti small
molecul pan-her inhibitor result materi million peak
aslan addit asset appear promis aslan two addit
promis asset well partner program
develop along develop partnership focus
inhibit modybodi novel antibodi fragment
technolog promis novel dhodh inhibitor phase
develop aml could materi potenti aml solid
tumor type dhodh may relev tripl neg breast
cancer tnbc hepatocellular carcinoma novel il-
inhibitor earli stage develop aslan look
establish proof-of-concept sever atop dermat asthma prior
outlicens molecul molecul upcom catalyst
expect program could also add materi valu aslan
oper time
confer
activ
tumor
blackwel et al pan-erbb inhibit superior select erbb inhibit
preclin model signal multipl erbb receptor american associ cancer research
chemic biolog aspect inflamm cancer
varlitinib differenti potenti advantag broad inhibit
demonstr select chart exhibit varlitinib could
advantag select inhibitor due broad-bas
inhibit famili also known erbb compris four receptor
tyrosin kinas egfr signal
member famili complex involv wide rang activ
hetero- homodim among famili member key signal
pathway util mani tumor co-express shown
involv resist mechan select egfr
associ
increas risk metastasi wors outcom tumor signal
sever famili member potenti sensit pan-
inhibitor compar select inhibitor sever tumor type
signal multipl famili member includ gastric hepatobiliari
pancreat ovarian therefor potenti respons
type pan-her inhibitor varlitinib origin
novel oral revers inhibitor target member erbb famili
either directli indirectli earli studi
varlitinib shown encourag clinic activ sever tumor type
includ gastric stomach biliari tract metastat breast
cancer along manag toxicity/toler profil like due part
revers inhibit
 highli select her-famili inhibit kinas
 encourag earli phase activ her-rel tumor
 potenti enrich trial design her-driven tumor
 potenti singl pivot studi biliari tract tumor
 possibl use breast cancer her-driven tumor
cancer develop varlitinib demonstr encourag
respons early-phas clinic studi her-rel cancer
notabl varlitinib demonstr solid efficaci phase
combin variou chemotherapi show overal respons rate
gastric tumor biliari tract tumor
pretreat patient exhibit encourag result hand
aslan embark multipl potenti pivot studi
varlitinib biliari gastric tumor gastric stomach tumor aslan
enrich popul co-express popul
estim gastric cancer approxim biliari tract
cancer express her-famili receptor accord aslan
geographi shortli biliari tract gastric stomach cancer other
wide preval asian countri aslan materi oper
experi exhibit aslan therefor look region drive
varlitinib rapid effici clinic trial enrol develop still
retain potenti approv major market world-wide varlitinib
current trial includ potenti singl pivot studi
condit differ geograph region sever
exhibit varlitinib relev cancer preval asia/pacif vs us
benefici twist us china commerci presenc plan aslan
focus develop oncolog therapeut though oper
understand cancer preval asia provid aslan
potenti effici drug develop import consider
aslan manag experi region led ceo carl firth
execut team year drug develop commerci
experi asia compani plan leverag broad experi
asia deep local relationship expedit drug develop
commerci effort use clinic data approv geographi
diseas consid orphan us eu materi
previou commerci experi asia china specif aslan plan
begin build target commerci organ china asian
market anticip potenti regulatori approv varlitinib
biliari tract gastric cancer plan similar target commerci effort
varlitinib us well
broadli activ pan-her inhibitor believ varlitinib potenti
materi consid line biliari tract cancer sever market
global possibl gastric cancer market
current treatment leav room addit therapeut option believ
varlitinib potenti world-wide peak revenu million
indic addit potenti breast colorect cancer given
aslan asln valuat aslan oper potenti
signific revenu earn variabl come quarter
year result valu oper use fully-tax risk-weight net
present valu methodolog major asset calcul npv
estim use asln us adss million repres five
ordinari share million ordinari share outstand aslan
advanc proprietari asset varlitinib biliari tract cancer
posit gastric cancer potenti other repres bulk
valu aslan oper
view despit varlitinib current
progress pivot studi continu activ
oncolog sector biotechnolog valu asln adss aslan
oper independ though assumpt could certainli chang
meaning clinic progress varlitinib
assum aslan oper independ assess total valu
aslan lead program asset per asln exhibit
tyrosin kinas inhibitor current enrol sever potenti
pivot studi aslan valuabl asset believ varlitinib
materi potenti therapeut line therapi potenti earlier
treatment biliari tract cancer remov econom
addit due activ manag toler believ may
potenti certain colorect breast cancer collect assum
broad use biliari cancer estim peak revenu million global
varlitinib aslan control commerci right us
china licens right eu possibl japan develop
partner use tumor beyond current repres upsid
estim intellectu properti protect anticip extend
least varlitinib estim valu asset aslan
aslan asset consider aslan
two addit promis asset novel dhodh inhibitor
aml novel inhibitor inflammatori
condit molecul earli stage develop
potenti add materi valu time earli
develop valu collect along partner
aslan net cash includ million cash debt million
estim million nol asset drag
gener corpor oper expens total share yield
total aslan asset
exhibit prior import event aslan
varlitinib preclin activ present multipl congress
varlitinib oral activ inhibitor egfr revers atp-
competit inhibitor dose-rel tumor growth inhibit observ
overexpress tumor model also achiev tumor regress lung
breast cancer vivo model bid well toler
per day day
biopharma launch phase dose-escal studi evalu varlitinib
toler pk profil hint efficaci patient advanc cancer
varlitinib initi phase data present multipl congress
develop expand data present aacr-nci-eortc
meet mace rothenberg ingram professor cancer research
preclin profil initi describedarray present preclin enter clinicarray begin broad phase develop data cholangiocarcinoma patientsupport develop biliari tract found ceo dr carl firthgoal leverag asia drug-develop licens varlitinib arrayiniti agreement develop clinic licens almiralliniti agreement develop rheumatoid pair biopsi gastric cancer datavarlitinib posit impact downstream signal rais seri bfund use advanc licens cslwill partner clinic poc econom initi line biliari cancerenrol biliari tract cancer deal almirallaslan control global commerci right rais seri cfund use advanc activ gastric pdx model aacranti-tumor activ signal inhibit support publish cell support amldhodh inhibit enabl differenti aml rais pre-ipo roundfund use advanc rais list taipei exchangelist oversubscrib ticker phase solid tumor data orr patient includ cholangiocarcinoma induc differenti preclin amlwork conduct w/ nci support move treetopp studi enrol patientposit data support us approv line biliari trial line gastric cancer expans data support us breast cancer data esmo asiavarlitinib activ line aml launchesreceiv ind singaporevvvjan varlitinib dealaslan control global commerci right varlitinibvvvvjan registr strategi chinapotenti approv biliari cancer orrvvvvapril activ hccpreclin data support investigator-initi trialvvvmay us ipo rais advanc varlitinib key datavvvv signific least import vvvvv import
vanderbilt-ingram cancer center show varlitinib well toler
bid typic tki fatigu nausea anorexia diarrhea rash
vomit drug concentr dose-depend achiev level
continu profound system inhibit patient
complet cohort bid stabl diseas bid regimen
chosen develop array expand trial enrol
addit patient onto phase herceptin-resist
breast family-driven cancer
varlitinib demonstr activ vs lapatinib
tumor growth inhibit compar lapatinib vivo xenograft model
co-express gastric cancer overexpress nsclc
cancer patient confirm co-express tend
greatest clinic benefit separ varlitinib bid achiev
regress target lesion patient cholangiocarcinoma subset
biliari tract cancer accompani tumor marker respons patient
ovarian patient cervic cancer patient stabl diseas
varlitinib use chemo combin array initi phase
program assess varlitinib combin capecitabin docetaxel
gemcitabin advanc metastat solid tumor data vivo
preclin tumor model express co-express
show low dose varlitinib increas anti-tumor activ trastuzumab
varlitinib chemistri summari phase data
present describ chemistri synthesi varlitinib ration
famili inhibitor approach summar varlitinib phase safeti
data set patient treat varlitinib monotherapi
chemo combin date monotherapi bid dlt
grade anorexia grade ast/alt elev varlitinib chemo agent
pk profil affect combin
aslan licens varlitinib array initi agreement
array aslan agre global develop varlitinib proof concept
initi target gastric cancer asia-bas develop program
posit proof concept aslan identifi partner
conduct phase develop commerci varlitinib up-front
payment made parti would split futur econom
phase partner prior
licens asset varlitinib
monotherapi chemotherapi combin evalu
patient agreement amend januari provid
aslan global commerci right varlitinib
aslan partner bristol myer squibb
partner enter innov agreement leverag aslan asia-bas
drug develop expertis acceler develop
clinic proof concept gastric lung cancer aslan obtain exclus
commerci right china australia korea taiwan asian market
deal structur also provid bristol rate option recal
aslan licens almiral initi
agreement aslan receiv global right develop almiral alm mc
rate dhodh inhibitor formerli rheumatoid
arthriti aslan agre fund advanc
rheumatoid arthriti end phase asia-pacif develop
program look partner phase develop
commerci time licens single-dos shown
well toler healthi volunt agreement subsequ
amend provid aslan global commerci right
phase mad studi begin singapor singapor
health scienc author approv clinic trial applic evalu
multipl ascend dose phase studi assess safeti
toler pk
varlitinib top-line data gastric cancer pair biopsi studi
phase pair biopsi trial conduct seoul nation univers hospit
enrol patient refractori recurr metastat gastric carcinoma
amplifi tumor tumor co-express egfr
tumor biopsi taken therapi analyz
downregul key signal pathway data present
octob primarili fund clinic develop varlitinib gastric cancer
aslan establish presenc taiwan aslan open offic
taipei februari manag local clinic manufactur activ
develop limit asx rate receptor-alpha subunit
antibodi inhibit signal asthma
clinic proof concept primarili site asia partner
program phase commerci activ assess
patient moder persist sever allerg asthma refractori
exist therapi atop dermat
varlitinib safeti studi launch taiwan aslan dose first
patient safeti studi taiwan explor safeti toler
varlitinib combin chemotherapi doublet cisplatin/fu
cisplatin/capecitabin treatment advanc solid tumor includ
varlitinib esmo phase pair biopsi data advanc
gastric cancer varlitinib monotherapi bid day led
biolog activ co-express amplifi gastric cancer
evalu pharmacodynam data set co-express
reduct pmapk activ cell prolifer regul
day
cellular marker prolifer upregul tunel
measur cell apoptosi activ reduct pakt signal
phase solid tumor patient posit patient
solid tumor success dose-escal treat least
day qd bid regimen dual cmet ron inhibitor
safe well toler dose evalu achiev long-term
stabl diseas partial respons certain tumor type addit
potent inhibit plasma biomark ron activ
collabor explor genom background varlitinib hyper
respond understand gastrointestin cancer aslan partner
act genom explor genom signatur patient
achiev outsiz respons varlitinib also enter memorandum
understand nation cancer centr singapor ncc enhanc
studi new therapeut common form gastrointestin cancer
preval asia gastric cancer hepatocellular carcinoma liver
cholangiocarcinoma memorandum provid collabor project
explor preclin research jointli conduct clinic trial diseas
symposium asia
varlitinib grant orphan drug design fda
cholangiocarcinoma subset biliari tract cancer orphan
design qualifi aslan develop incent provid
period market exclus protect gener entri
clearanc initi varlitinib phase cholangiocarcinoma
aslan receiv clearanc ind equival
singapor taiwan evalu varlitinib
patient
varlitinib licens hyundai pharmaceut south korea
aslan licens varlitinib develop commerci right hyundai
rate treatment cholangiocarcinoma south
korea aslan elig receiv undisclos regulatori commerci
mileston royalti product sale
revis deal almiral give aslan control
part revis agreement aslan receiv global right develop
commerci oncolog use exclud topic
dermatolog indic aslan pay almiral million
develop million regulatori mileston tier mid-single-
digit royalti aslan licens technolog pay almiral sublicens
fee
close januari primarili fund develop varlitinib
expand applic
varlitinib data gastric cancer model single-ag
gastric cancer patient-deriv
xenograft scid mice over-express protein activ
dose-depend tumor stasi observ bid regress
achiev bid varlitinib shown inhibit multipl cell
prolifer surviv pathway mapk other data correl
well phase pair biopsi trial
aslan open offic china aslan open shanghai offic
april manag local clinic manufactur activ
varlitinib data hepatocellular carcinoma model
single-ag varlitinib activ pdx model co-
express complet tumor regress achiev bid
drug well toler dose analysi suggest varlitinib
stop cell prolifer drove apoptosi
varlitinib grant fda orphan drug design gastric cancer
orphan design qualifi aslan develop incent
provid period market exclus protect gener entri
aslan rais million aslan rais million pre-ipo
fund primarili advanc develop varlitinib pipelin
reacquir bristol-my august bristol reacquir
right china australia korea taiwan asian
market aslan receiv million up-front elig
million pre-commerci mileston royalti global sale
transact valid aslan strategi rapidli attain high-qual
clinic leverag asian drug develop expertis
aslan gain global right ron antibodi
aslan licens global right develop commerci novel io
antibodi target recepteur dorigin nantai ron singapor
agenc scienc technolog research aslan respons
design clinic develop program complet
preclin develop
paper publish cell identifi dhodh target
aml syke et al identifi dhodh potenti key target aml drug
develop inhibit dhodh enzym shown enabl myeloid
differenti human mous aml cell deplet function
leukemia-initi cell addit dhodh inhibit may broad
util across aml subtyp
aslan gain option preclin modybodi technolog
aslan enter research collabor licens agreement
nanyang technolog univers singapor ntu develop modybodi
target aslan exclus option obtain global right
program modybodi novel stabil heavi chain monoclon
penetr due small size customiz natur pk
technolog potenti advantag
encourag top-lin phase data varlitinib breast cancer
varlitinib plu capecitabin compar tykerb lapatinib plu
capecitabin second-lin therapi breast cancer patient
progress herceptin trastuzumab among patient therapi
least month tumor shrinkag week significantli greater
subset orr vs varlitinib lapatinib
respect differ observ os
aslan enter research collabor singapor
aslan collabor cancer scienc institut singapor csi
nation univers cancer institut singapor nci evalu
mono combin therapi hematolog malign
enrol begin phase trial varlitinib biliari tract
cancer japan februari aslan enrol first patient onto phase
trial varlitinib solid tumor biliari tract cancer japan trial
enrol patient assess safeti toler varlitinib
monotherapi combin capecitabin success complet
trial support enrol japanes patient onto biliari tract cancer
aslan list taipei stock exchang june aslan
ordinari share list taipei stock exchang tpex
code list rais million total
varlitinib encourag earli phase solid tumor data
patient advanc solid tumor receiv escal dose varlitinib
either cisplatin/capecitabin cycl
varlitinib monotherapi patient evalu respons includ
pr stabl diseas progress
respons cholangiocarcinoma deep durabl includ patient
reduct liver tumor size cycl cr liver lesion
cycl anoth patient measur lesion liver biliari
tract achiev long-term diseas control month diarrhea
occur grade higher case control
standard loperamid imodium
preclin data support use aml
shown induc differenti aml blast cell line preclin studi
conduct collabor cancer scienc institut
singapor nation univers cancer
induct aml blast cell differenti associ apoptosi ie cell
death normal aml bone marrow data
support move phase develop relapsed/refractori aml
varlitinib bid dose identifi combin
cisplatin/capecitabin
june global pivot treetopp studi biliari tract cancer enrol
first patient first patient enrol onto global pivot treetopp
studi design support acceler approv fda studi enrol
biliari tract cancer patient fail line treatment receiv
varlitinib plu capecitabin capecitabin site globallyth trial
led dr milind javl md anderson cancer center base
discuss fda minimum patient need enrol
us site support us approv co-primari endpoint orr
patient aslan enrol first patient onto phase program
varlitinib plu folfox vs folfox first line treatment advanc
metastat gastric cancer co-express phase portion
enrol patient site asia europ assess primari
endpoint chang target tumor size week disappoint top-line
phase result present januari
varlitinib clinic develop begin partner nation
univers cancer institut singapor nci initi first clinic trial
varlitinib patient advanc metastat hepatocellular carcinoma
phase trial evalu enrol expans
cohort patient diseas progress line therapi
sorafenib trial assess safeti efficaci predict biomark
analysi aslan contribut varlitinib partial fund
varlitinib phase breast cancer data esmo asia patient
metastat breast cancer fail trastuzumab random
capecitabin plu bid varlitinib daili lapatinib
primari endpoint percentag chang tumor reduct
week tumor size reduct numer greater varlitinib vs
orr similar vs patient remain
studi day sensit analysi demonstr statist
signific higher reduct tumor size varlitinib vs
one-sid numer superior orr vs
common ae diarrhea varlitinib arm diarrhea
palmar-plantar erythrodysaesthesia syndrom occur
lapatinib arm intend exposur percentag intend dose
lower varlitinib
ind approv singapor kick phase aml
phase studi initi enrol relapsed/refractori aml patient
site singapor australia assess
monotherapi dose day
progress primari endpoint rate complet remiss
complet remiss incomplet bone marrow recoveri expans
cohort enrol addit patient potenti combin
jan revis array deal give aslan control varlitinib part
revis agreement aslan paid array up-front fee million array
also entitl receiv addit payment million within
month mileston tier low-double-digit royalti
base net sale varlitinib addit aslan also expect pay
array fee payment receiv sublicens varlitinib
right undisclos amount
jan favor regulatori pathway china announc follow
discuss chines fda cfda posit aslan expect file
approv biliari tract cancer base orr single-arm
pivot trial patient aslan announc close trial
part pipelin priorit
april varlitinib preclin hepatocellular carcinoma data
studi conduct collabor nation cancer centr
singapor design demonstr varlitinib activ patient-
deriv xenograft pdx model studi molecular mechan
varlitinib tumor suppress anti-angiogen potenti varlitinib
demonstr tumor regress vessel normal erbb-depend
mutat beta-catenin hepatocellular carcinoma pdx model
may aslan rais million us ipo aslan list american
depositori share adss nasdaq global market rais million
million net sale million adss fund
develop varlitinib equal ordinari share list
june new varlitinib phase data data phase
trial evalu varlitinib carboplatin/paclitaxel /- trastuzumab
advanc solid tumor varlitinib bid day on/off combin
paclitaxel identifi recommend dose addit
trastuzumab determin safe
advanc clinic aslan submit clinic
trial applic initi phase develop fulli human
monoclon antibodi specif bind inhibit
activ treatment atop dermat asset
licens reach proof concept current plan call
out-licens phase commerci activ
exhibit potenti upcom catalyst aslan
line gastric cancer datatumor reduct support expans phase interim data amlencourag updat dose optim interim line biliari cancer updateenrol on-going find support expans china line biliari cancer studi updateaslan close studi part pipelin dose optim amlposit dose-find move expans cohort complet sad trialiniti look pk/pd treetopp readout line biliari cancerorr support commerci partnership eu japanaslan maintain control us china marketsvvvv signific least import vvvvv import
interim phase data aml encourag interim data
dose-rang monotherapi portion phase studi aml
patient present aslan expect complet dose-
escal portion could support move expand
patient cohort allow dhodh inhibitor combin
standard induct chemotherapi progress primari endpoint
rate complet remiss complet remiss incomplet bone
marrow recoveri data could provid basi discuss potenti
pathway acceler approv fda dhodh inhibit
promis biolog myeloid cell differenti
varlitinib phase gastric cancer data data
phase portion measur folfox /- varlitinib patient co-express
elev express inelig
herceptin could support expans global phase trial could
potenti use support fda approv posit outcom base
tumor reduct week base one-sid p-valu
signific unfortun data note posit phase portion
studi expect enrol addit patient evalu os
primari endpoint continu
varlitinib interim phase data line biliari tract cancer
phase studi evalu gemcitabine/cisplatin /- varlitinib line
biliari tract cancer encourag earli data present gi
januari varlitinib combin gemcitabine/cisplatin gem/ci show
orr diseas control dcr orr dcr
dose dose-escal phase portion continu
determin provid basi expans plan phase
placebo-control studi patient per arm assess primari
endpoint posit aslan would begin patient phase studi
aslan close singl arm trial china varlitinib line
biliari tract cancer follow discuss chines fda aslan initi
expect leverag trial acceler pathway approv china
base orr data single-arm trial varlitinib plu capecitabin
patient progress prior chemotherapi base data first
rate aslan implement protocol amend ensur patient enrol
studi receiv appropri first-lin therapi exist
protocol varlitinib need statist exceed orr
consid success secondari endpoint studi includ os
top-line data follow amend expect global
random treetopp studi aslan close singl arm china trial part
januari restructur
partnership south korea aslan ink deal biogenet
south korea cover varlitinib up-front
mileston up-front mileston
tier royalti mid-twenti
varlitinib global pivot treetopp result line biliari tract
patient global site evalu varlitinib capecitabin vs capecitabin
alon co-primari endpoint orr statist analysi
plan allow primari success either endpoint signific one-sid
level endpoint signific one-sid level
either co-primari endpoint posit aslan plan file
acceler approv us enrol complet januari
top-line data expect
possibl licens varlitinib region right aslan recent
fund million april expect fund expens surround
varlitinib pivot treetopp studi biliari tract cancer aslan global
right varlitinib though believ compani licens molecul
eu japan would expect discuss heat late-stag
pivot clinic data emerg
sinc aslan oncology-focus
compani modest infrastructur signific nich regard
asia drug develop expertis reason chanc larger
industri suitor could emerg find compani oper attract
time event alway challeng predict though
awar build varlitinib robust differenti pan-her clinic
profil given potenti program believ possibl
though yet includ formal npv calcul
aslan focus develop oncolog therapeut though
materi benefici twist understand cancer preval
asia combin asia-bas develop platform provid
potenti compani develop drug effici could
achiev us eu major asian regulatori bodi japan
pharmaceut medic devic agenc pmda china food
drug administr cfda recent becom progress
approach toward drug develop exampl japan first approv
novel inhibitor opdivo nivolumab unresect melanoma
taiwan first approv gilotrif afatinib non-smal cell lung cancer
pmda introduc first acceler regulatori pathway sakigak
design state council china introduc seri
reform allow import drug approv use foreign data
dramat shorten approv timelin implement
addit recent data publish fda show asian countri
contribut global studi decad reach
level qualiti demand intern regul
exhibit asian preval cancer research led asian clinic
center asian investig
asia-bas clinic trial acceler develop addit
focus certain tumor type biliari tract gastric stomach cancer
other wide preval asian countri aslan
materi oper experi exhibit work lead
center asia exhibit recruit rate clinic trial
significantli increas nearli doubl rate us japan biliari
tract cancer two three time higher rate gastric cancer south
korea taiwan even cancer type preval higher
interest deep
asian market particularli
patient asia may easili recruit due fewer compet studi
larg patient pool aslan therefor look region china
japan south korea southeast asia drive varlitinib rapid effici
clinic trial enrol develop still retain potenti
approv major market world-wide varlitinib current trial includ
potenti singl pivot studi condit
differ geograph region sever import near-term data
aslan
manag experi region compani plan leverag
intern presenc broad experi asia materi knowledg
diseas
local relationship expedit drug
develop manag collect total year
china though expect
outlicens varlitinib eu possibl japan given manag
materi previou commerci experi asia china specif aslan
plan build target commerci organ china asian
market ahead potenti regulatori approv varlitinib biliari tract
cancer gastric cancer plan similar target commerci effort
varlitinib us
varlitinib background/summari aslan varlitinib also known
promis agent pivot develop
advanc metastat biliari tract cancer phase program
gastric cancer indic high unmet need
new treatment varlitinib potent oral revers small molecul pan-
inhibitor direct activ receptor
potenti expand therapeut activ varlitinib beyond
egfr select agent cancer driven combin
signal given abil inhibit downstream
growth pathway importantli varlitinib revers bind contribut
manag gi toler profil grade diarrhea less
patient treat compar favor irrevers pan-her
inhibitor nerlynx neratinib puma biotechnolog rate
earli phase clinic studi suggest varlitinib appear gener well-
toler singl agent combin chemotherapi
standard care
varlitinib evalu patient monotherapi
combin multipl cytotox agent demonstr activ
biliari tract gastric breast colorect cancer global pivot
treetopp studi line biliari tract cancer expect readout
could support potenti us approv molecul fda
orphan drug design gastric cancer cholangiocarcinoma
potenti broad-bas activ underpin peak varlitinib revenu estim
million
exhibit varlitinib structur activ
wallac select inhibitor erbb-famili receptor tyrosin kinas aacr annual meet
her/erbb famili background wide implic tumor genesi
her/erbb famili receptor subfamili four close relat human
play import role
activ signal pathway cellular prolifer surviv one
receptor overexpress abnormally/mut activ
number cancersbreast lung colon stomach pancreat ovari brain
prostat kidney result receptor primarili egfr
focu robust develop target therapeut agent
chang treatment paradigm sever preval cancer type
includ breast cancer account breast
cancer egfr amplif mutat non-smal cell lung cancer
wieduwilt moasser
exhibit erbb famili growth factor receptor
her/erbb receptor tyrosin signal complex receptor famili
key signal pathway util mani tumor co-express
shown involv resist mechan select egfr
inhibitor growth factor signal member
famili complex involv wide rang activ hetero-
dimer kinas activ mani tumor type co-express multipl
her/erbb receptor ligand redund homo-and heterodim
mapk pathway cancer erbb receptor undergo
variou alter human tumor aberr erbb signal gener
associ aggress diseas poor clinic outcom tumor
activ redund erbb dimer refractori select erbb inhibitor
tumor signal though sever member famili
potenti sensit broad-act famili inhibitor
compar select egfr inhibitor
wallac select inhibitor erbb-famili receptor tyrosin kinas aacr annual meet
adapt sabiosci
varlitinib also oral potent revers atp-
competit select small-molecul pan-her inhibitor varlitinib
high nanomolar molecular potenc egfr
abrog downstream signal mapk pathway
varlitinib also demonstr rel balanc inhibit kinas
exhibit also demonstr activ clinic import
mutant exon delet egfr truncat
form varlitinib high select famili
inhibit kinas wallac
biolog still emerg
demonstr variou group tumor escap mechan breast
cancer cell lead acquir resist inhibitor
trastuzumab lapatinib canfield et al cell cycl gala et al clinic
cancer research therefor use pan-her inhibitor
varlitinib potenti materi benefit treatment variou
exhibit varlitinib mechan action pan inhibit
revers inhibitor varlitinib bind receptor high drug
concentr releas bind concentr lower
result varlitinib absorb gi tract transient block gut
epitheli signal pathway perman bind receptor
gut epithelium gi tracta case irrevers inhibitor
chemic bond target receptor facilit
differenti gi toxic profil support rel low
rate grade higher diarrhea broad earli clinic develop
importantli improv toxic dynam achiev parallel
sustain varlitinib concentr tumor support continu target
inhibit
varlitinib clinic
exhibit varlitinib doublet chemo activ across broad rang tumor type focu turn
varlitinib earli clinic data activ doublet chemotherapi
tract gastric colorect breast cancer
receiv varlitinib doublet chemo either
cisplatin/capecitabin folfox xelox cycl varlitinib
monotherapi progress patient least prior line therapi
enrol enrich biomark analysi shown
diseas control rate orr rate notabl tumor reduct
cholangiocarcinoma exhibit specif orr
biliari tract gastric colorect cancer
respons breast cancer studi patient across biliari
tract gastric colorect achiev prolong pr stabl diseas
week safeti profil consist receptor inhibitor
preliminari data patient enrol present
exhibit varlitinib materi activ biliari tract cancer patient
data varlitinib drive deep respons biliari tract cancer
phase trial enrol biliari tract cancer patient prior
treatment discuss break-out phase data receiv
varlitinib combin platinum plu fluoropyrimidin chemotherapi
week varlitinib monotherapi given rel high presenc
express biliari tract tumor enrol studi
select express patient patient achiev
pr tumor reduct addit
patient stabl diseas control rate exhibit
respond durat respons week impli tumor
growth control varlitinib monotherapi though respons may
seem modest respons rate expect line patient standard-of-
care chemo capecitabin modest creat reason
potenti varlitinib success line biliari tract set
exhibit varlitinib gastric cancermodul downstream signal pathway co-express
et al phase iia studi evalu biolog activ co-express amplifi gastric cancer abstract
pakt
immunohistochemistri assess
data varlitinib inhibit import downstream signal gastric
cancer phase pair biopsi trial conduct seoul nation
univers hospit enrol patient relaps metastat gastric
carcinoma amplifi tumor tumor co-express
tumor biopsi taken day varlitinib bid
monotherapi analyz
modul downstream signal pathway data present
esmo show among evalu pharmacodynam
popul co-express reduct pmapk activ
cell prolifer regul cellular marker
prolifer upregul tunel measur cell apoptosi
survival/proliferation/growth effect varlitinib materi impact
downstream signal pathway suggest import pan-her activ
varlitinib activ trastuzumab-refractori breast cancer
patient metastat breast cancer fail prior trastuzumab
random capecitabin plu varlitinib bid
lapatinib qd primari endpoint percentag chang
tumor reduct week tumor size reduct numer greater
varlitinib vs one-sid exhibit left
though orr similar vs patient varlitinib
evalu due incomplet first cycl treatment patient
remain studi day sensit analysi
demonstr statist signific higher reduct tumor size
varlitinib vs one-sid numer superior orr
vs exhibit right data present esmo
exhibit varlitinib achiev encourag activ vs lapatinib trastuzumab-refractori mbc
al multicent open label random phase trial varlitinib versu lapatinib combin capecitabin patient
varlitinib appear gener manag common ae
varlitinib arm diarrhea grade appear
adequ control standard dose loperamid imodium
prophylaxi consid common event lapatinib arm
diarrhea
grade palmar-plantar
erythrodysaesthesia syndrom hand-foot syndrom grade
intend exposur percentag intend dose lower
varlitinib consid profil manag compar pan
inhibitor studi six patient withdrew consent within
first day one patient experienc grade seriou advers
event diarrhea assess drug-rel
exhibit varlitinib vet chemo combo
varlitinib thoroughli explor varlitinib
bid establish monotherapi combin singlet
doublet chemotherapi regimen frequent consid biliari tract
gastric metastat breast colorect cancer upcom
aslan present full data describ varlitinib bid day
on/off use combin paclitaxel typic use part
neoadjuv therapi breast cancer broad understand
varlitinib toxic profil combin cytotox agent may afford
physician flexibl consid varlitinib variou set cancer known
express receptor view
varlitinib appear manag gi toxic note
across varlitinib clinic trial decemb rate grade
diarrhea overal compar favor
grade diarrhea event report nerlynx neratinib extenet trial
report fda label view common drug-rel
fatigu grade nausea grade
one patient die due liver failur lead multi-organ failur sepsi
day treatment varlitinib capecitabin
determin possibl relat varlitinib across trial two
death note possibl relat varlitinib includ one
relat diseas progress worsen metastat breast cancer
anoth relat acut kidney injuri
varlitinib biliari tract cancer
biliari tract cancer background/summari biliari tract cancer rare
western hemispher estim patient diagnos us
rate asia-pacif region materi higher approxim
accord aslan diseas effect biliari system
respons transport bile fluid help break fat
liver gallbladd small intestin biliari tract cancer
consist intra-hepat extra-hepat cholangiocarcinoma cancer
bile duct repres case accord aslan cancer
gall bladder papilla vater carcinoma screen test
biliari cancer present often non-specificsuch pain
metastasi jaundic bile duct becom blockedmost patient
diagnos progress non-resect diseas diagnosi
gener made follow blood work liver function test ct scan
system accord dana-farb cancer institut
famili express materi biliari tract cancer specif
pathway drive biliari cancer fulli elucid date recent
data japan china discuss aslan suggest biliari tract
cancer tumor famili over-express wide
express accord aslan work support system review
co-express biliari tract malign galdi et al
show co-express rang biliari cancer
overexpress report cholangiocarcinoma
materi presenc aslan enrol all-com varlitinib
select famili express line set
exhibit overview biliari tract cancer
gemcitabine/oth platinum-bas chemo
vall et al new horizon precis medicin biliari tract cancer cancer discoveri
biliari tract cancer materi unmet need target agent
approv biliari tract cancer potenti cur treatment
option surgic resect complic aggress
diseas late-stag diagnosi result patient diagnos
non-resect diseas lamarca et al howev surgic resect
limit associ high rate recurr
surviv rate intrahepat cholangiocarcinoma well
poor outcom subtyp miyazaki et al major biliari
tract cancer patient elig surgic resect
surviv rate stage stage iv diseas lamarca et al
chemotherapi doublet
primarili use line set base phase work vall et al abc-
trial nejm demonstr doublet regimen achiev os
month month orr patient progress
lack consensu regard clinic util appropri
chemo regimen set fornaro et al retrospect
analysi lamarca annal oncolog line advanc biliari
cancer studi median os month month
varlitinib on-going trial biliari tract cancer
treetopp global pivot studi biliari tract cancer data
global pivot effort line therapi biliari tract cancer aslan
enrol patient phase treetopp studi agreement fda
treetopp enrol least patient us site includ md
anderson cancer center dr milind javl lead trial total
patient unselect express global site random
onto double-blind placebo-control trial evalu varlitinib plu
capecitabin co-primari endpoint orr independ
central review per recist exhibit statist analysi plan allow
primari success either endpoint signific one-sid level
endpoint signific one-sid level either
co-primari endpoint reach signific aslan plan file
acceler approv us secondari endpoint includ os durat
respons diseas control rate tumor shrinkag week top-line data
expect could support us launch earli
exhibit treetopp pivot studi design biliari tract cancer
treetopp benchmark success systemat review line chemo
consider success treetopp come systemat literatur
review studi evalu line chemotherapi advanc biliari
tract cancer lamarca et al drug approv
set analysi patient mean month ci
orr ci believ serv
appropri proxi
treetopp control arm addit
consider lamarca system review includ mean os
month diseas control rate previous report orr
varlitinib phase trial biliari tract cancer patient
replic treetopp support posit studi outcom view
anticip favor result file later year
potenti acceler approv us confirmatori trial would
need conduct indic full approv
varlitinib biliari tract cancer aslan enrol phase
trial varlitinib plu gemcitabine/cisplatin line biliari tract cancer
patient dose-escal phase portion determin
provid basi expans plan phase placebo-control
studi gem/ci /- varlitinib patient per arm assess primari
endpoint measur independ central review per recist
propos phase studi design detect minimum differ
week assum orr chemotherapi arm like
secondari endpoint orr diseas control rate durat respons
os phase trial expect support registr
set benchmark current line gemcitabine/cisplatin standard
care report trial vall et al nejm median os
month vs gemcitabin alon orr
doublet gemcitabin
varlitinib opportunity/econom biliari tract cancer aslan
seek approv varlitinib treatment line biliari tract cancer
near-term note approv target therapi
minim activ seen chemotherapi regimen current
estim price approxim per month therapi varlitinib
biliari tract cancer modest price increas per year initi
approv sought varlitinib line biliari tract cancer
note previous modest perform standard care
give varlitinib uniqu broad activ broad express
tumor reason probabl success
us estim patient diagnos biliari tract
cancer elig varlitinib line
current estim price approxim per month therapi
averag time drug month averag per patient
us estim acceler approv treetopp trial
complet us estim peak util patient
revenu exceed million set china estim
target line case annual assum price per
month averag per patient estim peak util china
patient sale nearli million though biliari tract
cancer preval may greater china take cautiou view
regard adopt trajectori uptak may limit cash pay
market initi reimburs establish market primarili
eu japan estim combin target popul
patient varlitinib therapi estim acceler approv
treetopp trial complet averag price per patient
eu japan similar peak util roughli
patient estim peak revenu market approach
million assum modest price increas per year outsid japan
assum modest declin
npv calculations/consider biliari tract cancer collect given
consider well expect varlitinib use well mid-
along patent term extens late estim
varlitinib peak revenu biliari tract cancer million
reason effici market molecul us china assum
licens varlitinib major market approxim
royalti array discount probabl approv given well-
vet biolog famili inhibit repres demonstr
activ varlitinib molecul estim fulli tax risk-weight
npv exhibit
exhibit varlitinib global market model biliari tract cancer
us biliari tract market biliari tract case w/ unresect undergo surgic respond doublet biliari tract biliari treated- averag month month tx d- price per month- price estim revenue- china biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- eu biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- japan biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- total biliari tract use us
exhibit varlitinib npv calcul aslan biliari tract cancer display
 biliari tract total revenu expens cog us royalti cog total expense- net rate tax effect rate total per valu npv/share biliari tract total revenu aslan- aslan expens cog china royalti cog total expense- net aslan- rate tax effect rate total per valu npv/share biliari tract royalti royalty- upfront/mileston mileston array- total revenu aslan- aslan expens payment array- royalti sg a- d- total expense- net aslan- rate tax effect rate total per valu npv/share
singapor enrol phase single-arm investig sponsor studi
varlitinib patient progress line nexavar sorafenib
lenvima lenvatinib dose-escal portion determin maximum
toler dose efficaci assess cohort
metastat breast cancer standard treatment metastat
breast cancer includ combin trastuzumab pertuzumab
taxan line treatment line treatment line
set clinician administ therapi combin t-
previous administ patient previous receiv
defin standard treatment patient popul
pan-her agent use set associ toxic
agent late-stag develop though
probabl weight possibl breast cancer use varlitinib
valu modest right assum revenu use
set model
promis oral dhodh inhibitor aml
summari oral avail potent
inhibitor dihydroorot dehydrogenas dhodh potenti
first-in-class agent acut myeloid leukemia aml shown
potenti induc blast cell differenti major aml cell
exhibit potent preclin activ roughli order
magnitud greater first-gener dhodh inhibitor improv
pk/pd profil allow full exposur achiev hour
half-lif eas toxic concern associ earlier
dhodh inhibitor aslan investig util phase
trial relapsed/refractori acut myeloid leukemia aml interim data
present addit preclin effort explor use solid
tumor includ triple-neg breast cancer tnbc hepatocellular
exhibit dhodh inhibitor mechan action
dhodh background dhodh ubiquit metabol enzym locat
inner mitochondria membran control rate-limit step de
novo pyrimidin synthesi essenti build block dna rna
also play role product adenosin triphosph atp
increas level support tumor growth surviv cancer
specif dhodh catalyz convers dho orotateth step
pyrimidin synthesi transfer enzym dho complex
electron-transport chain syke et al enzym known
mutat overexpress cancer syke et al inhibit
enzym shown trigger activ tumor suppressor
inhibitor approv autoimmun
indic aubagio teriflumid approv treatment relaps
form multipl sclerosi prodrug arava leflunomid approv
treat activ moderate-to-sever rheumatoid arthriti psoriat arthriti
molecul suffici dhodh inhibitor slow inflammatori
cell prolifer use chronic set materi
potent dhodh inhibitor may enabl success develop
oncolog indic molecul attempt first-gener
inhibitor unsuccess addit first-gener dhodh molecul
design higher dhodh potenc associ unaccept
toxic result off-target bind materi drug accumul
could requir year clear pharmacolog activ level
importantli chemic relat first-gener dhodh
exhibit potent gener dhodh inhibitor
overwhelm benefit all-tran
dhodh inhibit potenti role aml therapi goal aml
therapi overcom myeloid cell differenti blockad demonstr
differenti agent achiev cure rate small acut
syke et al cell recent publish work describ inhibit
dhodh enzym facilit myeloid differenti human mous aml
cell find base observ gene
downregul normal myeloid differenti express
major aml cell uncommon find given heterogen
malign
exhibit dhodh inhibit improv surviv primari leukemia left
lower leukemia-initi cell right secondari transplant mice
syke et al inhibit dihydroorot dehydrogenas overcom differenti blockad acut
use high throughput screen author identifi dhodh enzym
target activ compound downregul
hit librari compound find
support vitro vivo studi aml model show
dhodh inhibitor spark myeloid differenti result deplet
function leukemia-initi cell mechan dhodh-induc
myeloid differenti isnt fulli understand author postul
effect like involv combin inhibit nucleic acid synthesi
cell-cycl arrest chang post-transl glycosyl
data enabl differenti aml cell line dose
drove differenti human aml blast cell line
specif cell expos compound concentr
equival qd dose upregul cell
surfac marker normal immun cell exhibit left suggest
differenti aml blast granulocyt type white blood cell
drug exposur led format hallmark consist
normal human granulocyt activ granul cytoplasm
demonstr reduct nitro tetrazolium nbt
standard assay granulocyt exhibit right
exhibit activ aml cell line unrespons
improv pharmacokinet profil phase singl
multipl ascend dose studi conduct healthi
caucasian asian subject pk dose-proport
importantli accumul bodi issu
gener dhodh inhibitor singl dose drug exposur similar
race exhibit left stabil multipl dose exhibit
exhibit pharmacokinet support use oncolog set
state exposur qd achiev dhodh
inhibit exhibit green compar favor inhibit
maximum dost teriflunomid exhibit red accord aslan
phase aml data phase studi initi enrol
relapsed/refractori aml patient site singapor australia assess
monotherapi dose
day progress primari endpoint rate complet
remiss complet remiss incomplet bone marrow recoveri
dose-escal on-going establish optim dose aml prior
move expand patient cohort allow
combin standard induct chemotherapi data could provid
basi discuss potenti pathway acceler approv fda
exhibit activ aml cell line unrespons
emerg competit appear advanc
effort underway industri player activ pursu
dhodh target includ bayer bayri rate
current enrol phase dose-escal trial patient
advanc myeloid malign greater line therapi agio
rate late-stag preclin develop
dhodh inhibitor may day project ind
file dhodh interim phase readout
appear advanc program
summary/background compani preclin
potenti first- class fulli human monoclon antibodi target il-
receptor subunit inhibit signal
key cytokin trigger symptom allergi atop dermat red
itch well asthma symptom short breath wheez
cough aslan initi clinic develop sever
atop dermat posit proof concept hand aslan
seek partner phase commerci program licens
limit receiv econom
exhibit receptor antibodi mechan action
potenti advantag
narrow cellular distribut subunit target
regeneron pharmaceut review sanofi sni
rate dupix dupilumab potenti allow dose
lower volum frequenc dupix dose everi
week addit target subunit il-
receptor block type receptor contrast dupix
dose present cell macrophag avoid type
receptor may improv safeti profil
partner bristol-my squibb
aslan enter licens agreement bristol-my squibb
exclus right develop commerci
china australia korea taiwan select asian countri without
up-front payment bristol retain exclus right rest
world agreement aslan would fund develop
proof concept develop plan would initi target
gastric cancer lung cancer aslan complet phase clinic
trial bristol licens exclus right aslan continu global
develop commerci aslan receiv
up-front payment million
could receiv addit
develop regulatori mileston million
advanc well undisclos royalti payment estim
aslan gain exclus global right develop manufactur
commerci varlitinib human anim therapeut diagnost
prophylact use goal fda approv us commerci
aslan paid million up-front pay addit million
later januari potenti mileston array includ million
develop million regulatori million commerci
event aslan also pay tier royalti low ten net sale
last patent claim year first commerci sale
countri countri addit aslan sublicens varlitinib anytim
januari array receiv up-front payment receiv
aslan undisclos amount sublicens royalti less
array receiv amount actual receiv aslan
array also receiv low- mid-single-digit percent proce
chang control scenario aslan agreement replac earli
agreement enter juli requir aslan partner varlitinib
follow clinic proof concept gastric cancer
varlitinib hyundai pharm co commerci varlitinib south korea
aslan enter licens agreement octob hyundai pharma
wherebi hyundai receiv option acquir right commerci
varlitinib treatment cholangiocarcinoma south korea aslan
elig receiv regulatori commerci mileston royalti
enter global licens agreement almiral may develop
initi treatment prevent
rheumatoid arthriti agreement amend decemb
march expand scope includ exclus world-wide licens
develop manufactur commerci product human
diseas primari focu oncolog except topically-
administ product non-melanoma skin cancer aslan gener
right sublicens consider amend aslan pay
almiral million develop million regulatori
mileston almiral receiv tier royalti mid-single-digit rang
net sale sublicens revenu earn aslan
enter global licens agreement limit may develop
monoclon antibodi antigen bind
fragment thereof treatment diagnosi prevent diseas
condit human up-front payment aslan fund
develop clinic proof-of-concept patient moder
persist sever allerg asthma refractori exist therapi
asian-focus develop program aslan right grant
commerci right third-parti upon establish clinic proof-of-concept
right commerci independ
aslan requir pay licens revenu receiv
regulatory/fda compani whose main busi
drug
develop aslan subject rigor development regulatori
requir us fda intern regulatori agenc
cfda china pmda japan new drug approv
maintain statu promot approv drug also strictli
regul fda relat agenc throughout globe also gener
though compani specif focu ethic prescript pharmaceut
place signific risk oper due oversight fda
government regulatori bodi believ specif risk time
greater research-bas drug develop
compani asln share materi depend clinic success
varlitinib lesser extent dhodh inhibitor preclin
pipelin aslan fail obtain licensur molecul compani
like experi extrem challeng circumst
gener
meaning revenu profit circumst asln share would
manufactur risk fda recent quit vigil regard
inspect drug manufactur plant aslan could subject addit
risk type fda regard manufactur varlitinib
program submit licensur us
approv
meaning problem aslan
manufactur oper contract accomplish goal
issu could materi asln share
commerci risk commerci infrastructur necessari penetr
hospit market varlitinib lesser extent appear
meaning hospit drug formulari accept often quit challeng
execut
consider experi asian drug develop clinic trial execut
aslan organ experi market drug
current sale forc materi commerci risk adopt
product exist compani unabl achiev signific product sale
necessari profit asln share could materi harm also
aslan attempt engag fail obtain commerci partner either
intern us market asln share potenti
payer may find valu proposit varlitinib accept insur
compani could requir rigor requir prior author
payment varlitinib payer significantli accept varlitinib
product demand could insuffici obtain profit materi
neg affect aslan busi moreov insur compani adopt
oner requir varlitinib demand product could
materi neg affect could also hinder profit
neg affect aslan revenu profit potenti
dilut risk aslan current cash balanc proce
recent us ipo fund oper multipl upcom catalyst
compani fail obtain necessari cash complet full
develop varlitinib global hire sale forc
us geographi asln share could substanti harm
addit potenti dilut may inhibit potenti materi asln
share advanc exist may off-put potenti investor
asln share
oncolog develop current develop
environ oncolog therapeut gener favor
guarante current develop climat remain place new
old challeng aris despit best effort aslan manag
team asln share potenti produc neg return holder
risk price asln may limit trade price
ordinari share tpex list tpex sinc june
code tpex set certain limit trade
volatil ordinari share current limit daili price
movement tpex given limit potenti increas
trade price adss may purchas may materi limit
base perceiv valu ordinari share tpex similarli
decreas trade price ordinari share tpex due
percept investor market may impact valu cross list
ordinari share adss follow us ipo may advers affect
liquid valu adss also may dilut liquid
secur one market may advers affect develop
activ trade market adss us addit currenc
fluctuat new taiwan dollar dollar may
advers impact valu adss
materi risk indirect competitor vaccin antibodi
immuno-oncolog molecul tki among other could present
materi challeng market penetr varlitinib patient
progress later line might affect earlier therapi therebi
truncat varlitinib potenti varlitinib toler may ultim
materi differenti tki efficaci may suffici
distinguish potenti exist competit aslan qualifi
foreign privat issuer requir file period report financi
statement sec frequent promptli domest compani
could limit investor interest addit right asln sharehold
may differ right typic offer sharehold
corpor aslan corpor affair govern articl
law govern cayman island corpor compani engag drug
develop market sale busi well common law
cayman island certain right respons sharehold
holder member board director cayman law differ
appli us corpor fiduciari duti director
cayman island exempt compani may fiduciari
duti director corpor differ may
creat materi advers chang holder right compar
us domicil corpor materi differ well
understood potenti owner prior purchas
product total- us aml global rev partner us global rev us global rev partner us other/collab proprietari drug revenu mileston royalti revenu royalti partners- up-front mileston total roylti upfnt milestn revenue- total aslan expens oper marginnmnmnmnmnmnmnmnmnm interest interest incom financ incom incom pre-tax marginnmnmnmnmnmnmnmnmnmeffect tax tax tax incom loss effect fulli marginnmnmnmnmnmnmnmnmnmoth comprehens incom loss comprehens incom ex-charg eff ex-charg comprehens incom eff o/ o/ share ordinari ex-charg aslan pharmaceut limit sec document btig estim contact inform robert bert hazlett manag director btig research year year growth -- -- expens sale --
 investments/mktb account prepaid current current properti equip intang refund total trade long-term debt liabil current long-term equiti ordinari capit accumul comprehens accumul equiti sharehold total liabil sharehold statement oper activitiesnet incom depreci stock-bas financ fx expens current receiv oper oper invest activ capit expenditur payment intang matur purchas payment intang asset invest financ activ issuanc prefer issuanc common stock proceeds/retir financ cash increas decreas end cash aslan pharmaceut limit sec document btig estim contact inform robert bert hazlett manag director btig research
btig cover compani mention report
appendix analyst certif import disclosur
